Assessment of STELARA (Ustekinumab) and Tumor Necrosis Factor Alpha Inhibitor Therapies in Patients With Psoriatic Arthritis in Standard Health-Care Practice; A Prospective, Observational Cohort
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2018
At a glance
- Drugs Ustekinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms PsaBio
- Sponsors Janssen Pharmaceutica
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
- 16 Jun 2018 Results (n=563) presented at the 19th Annual Congress of the European League Against Rheumatism.
- 13 Nov 2017 Planned End Date changed from 21 Dec 2020 to 30 Jun 2021.